N/A
Completed N=16
The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Source: ClinicalTrials.gov NCT01985542 ↗
Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Apr 2021
Primary outcomePrimary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
Summary
Allergic rhinitis might be caused by decreased resistance of nasal barrier to allergens and other environmental insults. About 20 % of the European population suffers from pollen allergies. Birch pollen allergic rhinitis is the most common allergic disease in the Scandinavia and it exists widely also in the Central Europe. Suffering and high costs of pollen allergies may be reduced by understanding the molecular biology of the nasal barriers during allergic response. Our aim is to observe the effect of season and birch pollen immunotherapy on the molecular biology of nasal epithelium and the microbiome.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Total Number of Differentially Expressed Transcripts. |
119; 49 | — |
| SECONDARY Percentage Change in Visual Analogue Scale Scores of Symptoms |
-68; 91 | — |
Eligibility Criteria
Inclusion Criteria
- allergic rhinoconjunctivitis of birch pollen OR healthy controls
Exclusion Criteria
- smoking, asthma, any other disease than allergic rhinoconjunctivitis, requiring constant medication
Data sourced from ClinicalTrials.gov (NCT01985542). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.